Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 52 (1974), S. 485-492 
    ISSN: 1432-1440
    Keywords: New erythrocyte G-6-PD variant ; Gd Frankfurt ; Structural abnormality ; Molecular weight ; Peptide analysis ; Amino acid substitution ; Lys → Glu ; Neue erythrocytäre G-6-PD-Variante ; Gd Frankfurt ; strukturelle Anomalie ; Molekulargewicht ; Peptidanalyse ; Aminosäurenaustausch ; Lys → Glu
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Eine neue, anomale erythrocytäre G-6-PD-Variante, Gd Frankfurt, wurde nach chromatographischer Reingung auf DEAE-Cellulose, durch fraktionierte Ammoniumsulfat-Fällung und zweimalige Gelfiltration auf das rund 14000fache angereichert. Mittels Gelfiltration wurde eine Molekulargewichtsbestimmung durchgeführt, ferner wurde der SH-Gruppen-Gehalt und die Hemmung der Aktivität durch N-Äthylmaleimid bestimmt. Im Vergleich zum Normalenzym, Gd B, fand sich — bei gleichem SH-Gruppen-Gehalt — ein von der Norm nur geringfügig abweichendes Molekulargewicht von 223 000 gegenüber 243 500 beim Normalenzym und eine etwas stärkere Hemmung durch N-Äthylmaleimid. Nach tryptischer Verdauung ergab die Peptidanalyse mittels Fingerprint-Verfahrens auf Kieselgel-S-Dünnschichtplatten ein abweichendes Verhalten für 1 Peptid, während die restlichen 39 Peptide die gleiche Lokalisation aufwiesen. Die Aminosäuren-Analyse dieser differienden Peptide deckte für die neue Variante einen Austausch von Lysin gegen Glutaminsäure auf.
    Notes: Summary A new, abnormal erythrocyte G-6-PD variant, Gd Frankfurt, was first purified chromatographically on DEAE cellulose. Further purification was performed by fractionate precipitation with ammonium sulfate and by double gel filtration on Sephadex G-200. By these procedures a nearly 14000-fold concentration was obtained. In this preparation as well as in a control preparation of the normal enzyme variant Gd B the molecular weight, the content of sulfhydryl groups and the inhibition of enzyme activity by N-ethylmaleimide was determined. The content of sulfhydryl groups was found to be the same as in the normal enzyme variant. The molecular weights are slightly different: for the abnormal enzyme variant the value obtained was 223 000, and 243 500 for the normal enzyme. The inhibition by N-ethyl-maleimide showed to be somewhat stronger in the abnormal variant than in the normal enzyme. Peptide analysis after tryptic digestion was performed by fingerprint technique on silica gel-starch thin layers. 39 peptides of the abnormal variant showed the same pattern as in the normal enzyme whereas one peptide was found in a differing localization. Amino acid analysis' of the differing peptides revealed a substitution of glutamic acid for lysine in the abnormal enzyme variant.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0584
    Keywords: Non-Hodgkin lymphoma ; Centrocytic lymphoma ; Centroblastic-centrocytic lymphoma ; Centroblastic lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Clinical data of 48 patients with centrocytic, 83 patients with centroblastic/centrocytic and 64 patients with centroblastic lymphoma who had entered a prospective multicenter study of the Kiel Lymphoma Study Group since October 1975 were compared. Advanced (stage IV) disease at time of diagnosis, predominantly due to bone marrow infiltration, was most frequent in centrocytic (69% of patients) and in centroblastic/centrocytic (51% of patients) lymphomas as compared to only 28% of patients with centroblastic lymphoma. High survival probability of patients with localized centrocytic and centroblastic/centrocytic lymphomas after radiotherapy, contrasting with a worse prognosis of corresponding patients with centroblastic lymphoma, is compatible with the classification of these lymphoma entities as neoplasias of low-grade malignancy. However, as shown by this prospective and previous retrospective trials overall survival probability of patients with advanced centrocytic lymphoma was inferior to that observed in corresponding patients with centroblastic/centrocytic lymphoma. These findings suggest the possibility that patients with advanced centrocytic lymphoma occupy an intermediate position between typical low-grade and typical high-grade malignant non-Hodgkin lymphomas.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...